Among 5 patients with protocol-defined virologic failure at Week 48 in this study, none experienced HIV-1 RNA > 200 copies/mL.
Switching to 2-drug ART did not increase risk of virologic suppression, serious non-AIDS events, or death in virologically suppressed persons with HIV.
Analysis of data from 4 international trials of switching to BIC/FTC/TAF found high rate of efficacy and favorable tolerability in older virologically suppressed patients.
During the first 9 months following a switch from TDF- to TAF-based ART, estimated annual rates of weight gain ranged from 1.80-4.47 kg across regimens. These gains subsequently slowed or plateaued but occurred regardless of concomitant INSTI use.
More than 2 years after the switch to DOR/3TC/TDF, adjusted mean weight gains ranged from 1.2-1.4 kg with no evident differences by sex, race, or ethnicity. The majority of patients (~ 70%) experienced < 5% weight gain at Week 144 of the study.
Lipid and fasting insulin changes favored the switch to 2 drugs with a lower risk of insulin resistance compared with continued 3-drug or 4-drug TAF-based regimens in this international study of virologically suppressed adults.
Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.
Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.
In an updated analysis of data through April 2020, NTD prevalence among infants of women who received DTG at conception continues to be slightly higher than among those without HIV or who received non-DTG ART.
Results demonstrate that this novel investigational first-in-class HIV-1 capsid inhibitor was generally well tolerated after single-dose administration in healthy volunteers, with PK supportive of a 6-month dosing interval.